Drug Profile
Trilaciclib - G1 Therapeutics
Alternative Names: COSELA; G1T 28; G1T28-1Latest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator G1 Therapeutics
- Developer Boehringer Ingelheim; G1 Therapeutics; Quantum Leap Healthcare Collaborative; Simcere Pharmaceutical Group
- Class Amines; Antineoplastics; Aza compounds; Chemoprotectants; Cyclohexanes; Ketones; Piperazines; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Radioprotectives; Small molecules; Spiro compounds
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Myelosuppression; Small cell lung cancer
- Phase III Colorectal cancer; Triple negative breast cancer
- Phase II Bladder cancer; Breast cancer; Non-small cell lung cancer
- No development reported Cancer
Most Recent Events
- 01 Mar 2024 G1 Therapeutics terminates a phase II PRESERVE3 trial in Bladder cancer (Metastatic disease, First-line therapy, Combination therapy, Late-stage disease) in Georgia, Hungary, Spain, France, USA (IV) as the sponsor is no longer pursuing trial for the indication (NCT04887831)
- 10 Jan 2024 G1 Therapeutics initiates enrolment in the phase II trial for Triple negative breast cancer (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease, Inoperable/Unresectable) in USA (IV) (NCT06027268)
- 08 Jan 2024 Efficacy data from a phase II trial in Triple negative breast cancer released by G1 Therapeutics